Clinical Trial Update: Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of binimetinib and encorafenib for metastatic melanoma with CNS metastases is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Metastases
• Melanoma

Drugs mentioned

• Binimetinib (binimetinib)
• Encorafenib (encorafenib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma | Phase 2 | Status: RECRUITING